![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PROS1 |
Gene summary for PROS1 |
![]() |
Gene information | Species | Human | Gene symbol | PROS1 | Gene ID | 5627 |
Gene name | protein S | |
Gene Alias | PROS | |
Cytomap | 3q11.1 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | A0A0S2Z4K3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5627 | PROS1 | NAFLD1 | Human | Liver | NAFLD | 3.26e-10 | 1.06e+00 | -0.04 |
5627 | PROS1 | S43 | Human | Liver | Cirrhotic | 5.33e-10 | 5.26e-02 | -0.0187 |
5627 | PROS1 | HCC1_Meng | Human | Liver | HCC | 1.71e-81 | 4.33e-01 | 0.0246 |
5627 | PROS1 | HCC2_Meng | Human | Liver | HCC | 1.86e-15 | -2.56e-01 | 0.0107 |
5627 | PROS1 | cirrhotic1 | Human | Liver | Cirrhotic | 1.01e-05 | -2.28e-01 | 0.0202 |
5627 | PROS1 | cirrhotic2 | Human | Liver | Cirrhotic | 1.18e-05 | -9.85e-02 | 0.0201 |
5627 | PROS1 | HCC1 | Human | Liver | HCC | 2.39e-04 | 4.11e+00 | 0.5336 |
5627 | PROS1 | HCC2 | Human | Liver | HCC | 8.30e-06 | 3.81e+00 | 0.5341 |
5627 | PROS1 | Pt13.b | Human | Liver | HCC | 2.05e-06 | -6.83e-02 | 0.0251 |
5627 | PROS1 | S015 | Human | Liver | HCC | 2.60e-02 | 6.44e-01 | 0.2375 |
5627 | PROS1 | S028 | Human | Liver | HCC | 2.63e-18 | 1.11e+00 | 0.2503 |
5627 | PROS1 | S029 | Human | Liver | HCC | 5.67e-19 | 1.27e+00 | 0.2581 |
5627 | PROS1 | male-WTA | Human | Thyroid | PTC | 5.36e-55 | 6.86e-01 | 0.1037 |
5627 | PROS1 | female-WTA | Human | Thyroid | PTC | 6.34e-05 | 3.26e-01 | 0.0726 |
5627 | PROS1 | PTC01 | Human | Thyroid | PTC | 4.98e-54 | 1.03e+00 | 0.1899 |
5627 | PROS1 | PTC03 | Human | Thyroid | PTC | 5.01e-06 | 3.98e-01 | 0.1784 |
5627 | PROS1 | PTC04 | Human | Thyroid | PTC | 4.37e-34 | 8.26e-01 | 0.1927 |
5627 | PROS1 | PTC05 | Human | Thyroid | PTC | 3.20e-58 | 2.47e+00 | 0.2065 |
5627 | PROS1 | PTC06 | Human | Thyroid | PTC | 1.21e-89 | 2.19e+00 | 0.2057 |
5627 | PROS1 | PTC07 | Human | Thyroid | PTC | 1.65e-119 | 2.03e+00 | 0.2044 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0042730 | Liver | NAFLD | fibrinolysis | 15/1882 | 25/18723 | 1.26e-09 | 2.30e-07 | 15 |
GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
GO:0050819 | Liver | NAFLD | negative regulation of coagulation | 21/1882 | 53/18723 | 1.33e-08 | 1.69e-06 | 21 |
GO:1900046 | Liver | NAFLD | regulation of hemostasis | 24/1882 | 68/18723 | 1.84e-08 | 2.09e-06 | 24 |
GO:0061045 | Liver | NAFLD | negative regulation of wound healing | 26/1882 | 78/18723 | 1.86e-08 | 2.09e-06 | 26 |
GO:19030347 | Liver | NAFLD | regulation of response to wounding | 41/1882 | 167/18723 | 4.70e-08 | 4.58e-06 | 41 |
GO:0050818 | Liver | NAFLD | regulation of coagulation | 24/1882 | 71/18723 | 4.80e-08 | 4.60e-06 | 24 |
GO:00075994 | Liver | NAFLD | hemostasis | 49/1882 | 222/18723 | 9.23e-08 | 7.59e-06 | 49 |
GO:00075964 | Liver | NAFLD | blood coagulation | 48/1882 | 217/18723 | 1.16e-07 | 8.81e-06 | 48 |
GO:00508174 | Liver | NAFLD | coagulation | 48/1882 | 222/18723 | 2.40e-07 | 1.61e-05 | 48 |
GO:00458617 | Liver | NAFLD | negative regulation of proteolysis | 66/1882 | 351/18723 | 4.02e-07 | 2.58e-05 | 66 |
GO:1903035 | Liver | NAFLD | negative regulation of response to wounding | 26/1882 | 94/18723 | 1.18e-06 | 5.66e-05 | 26 |
GO:00513467 | Liver | NAFLD | negative regulation of hydrolase activity | 62/1882 | 379/18723 | 8.11e-05 | 1.66e-03 | 62 |
GO:00525477 | Liver | NAFLD | regulation of peptidase activity | 72/1882 | 461/18723 | 1.03e-04 | 2.03e-03 | 72 |
GO:00525487 | Liver | NAFLD | regulation of endopeptidase activity | 67/1882 | 432/18723 | 2.17e-04 | 3.70e-03 | 67 |
GO:00508787 | Liver | NAFLD | regulation of body fluid levels | 60/1882 | 379/18723 | 2.61e-04 | 4.23e-03 | 60 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
PROS1 | AXL | PROS1_AXL | PROS | Breast | ADJ |
PROS1 | AXL | PROS1_AXL | PROS | Breast | DCIS |
PROS1 | AXL | PROS1_AXL | PROS | Breast | Healthy |
PROS1 | AXL | PROS1_AXL | PROS | Cervix | ADJ |
PROS1 | AXL | PROS1_AXL | PROS | Cervix | CC |
PROS1 | AXL | PROS1_AXL | PROS | Cervix | Healthy |
PROS1 | AXL | PROS1_AXL | PROS | Endometrium | ADJ |
PROS1 | AXL | PROS1_AXL | PROS | Endometrium | AEH |
PROS1 | AXL | PROS1_AXL | PROS | Esophagus | ESCC |
PROS1 | AXL | PROS1_AXL | PROS | GC | ADJ |
PROS1 | AXL | PROS1_AXL | PROS | HNSCC | Healthy |
PROS1 | AXL | PROS1_AXL | PROS | HNSCC | OSCC |
PROS1 | AXL | PROS1_AXL | PROS | HNSCC | Precancer |
PROS1 | AXL | PROS1_AXL | PROS | Liver | HCC |
PROS1 | AXL | PROS1_AXL | PROS | Liver | Healthy |
PROS1 | AXL | PROS1_AXL | PROS | Liver | Precancer |
PROS1 | AXL | PROS1_AXL | PROS | Lung | AAH |
PROS1 | AXL | PROS1_AXL | PROS | Lung | ADJ |
PROS1 | AXL | PROS1_AXL | PROS | Lung | AIS |
PROS1 | AXL | PROS1_AXL | PROS | Lung | IAC |
Page: 1 2 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PROS1 | SNV | Missense_Mutation | novel | c.601N>T | p.Asp201Tyr | p.D201Y | P07225 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-69-7978-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PROS1 | SNV | Missense_Mutation | c.335N>T | p.Ser112Ile | p.S112I | P07225 | protein_coding | deleterious(0) | benign(0.365) | TCGA-69-7979-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PROS1 | SNV | Missense_Mutation | c.810N>T | p.Lys270Asn | p.K270N | P07225 | protein_coding | deleterious(0) | possibly_damaging(0.521) | TCGA-73-7499-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
PROS1 | SNV | Missense_Mutation | novel | c.1481N>C | p.His494Pro | p.H494P | P07225 | protein_coding | deleterious(0.01) | benign(0.021) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
PROS1 | SNV | Missense_Mutation | novel | c.1429N>T | p.Val477Phe | p.V477F | P07225 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PROS1 | SNV | Missense_Mutation | c.1735G>T | p.Val579Phe | p.V579F | P07225 | protein_coding | deleterious(0) | probably_damaging(0.919) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PROS1 | SNV | Missense_Mutation | c.153G>T | p.Gln51His | p.Q51H | P07225 | protein_coding | deleterious(0) | benign(0.382) | TCGA-95-7039-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
PROS1 | SNV | Missense_Mutation | c.635N>T | p.Cys212Phe | p.C212F | P07225 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-97-7554-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | alimta | SD | |
PROS1 | SNV | Missense_Mutation | c.1901N>A | p.Ala634Asp | p.A634D | P07225 | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-97-7938-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PROS1 | SNV | Missense_Mutation | novel | c.888N>T | p.Lys296Asn | p.K296N | P07225 | protein_coding | tolerated(1) | benign(0) | TCGA-99-7458-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | tarceva | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5627 | PROS1 | DRUGGABLE GENOME | Warfarin | WARFARIN | ||
5627 | PROS1 | DRUGGABLE GENOME | Lusutrombopag | LUSUTROMBOPAG | ||
5627 | PROS1 | DRUGGABLE GENOME | avatrombopag | AVATROMBOPAG | ||
5627 | PROS1 | DRUGGABLE GENOME | Avatrombopag | AVATROMBOPAG | ||
5627 | PROS1 | DRUGGABLE GENOME | ethinyl estradiol / norelgestromin | |||
5627 | PROS1 | DRUGGABLE GENOME | MENADIONE | MENADIONE | ||
5627 | PROS1 | DRUGGABLE GENOME | Estradiol | ESTRADIOL | ||
5627 | PROS1 | DRUGGABLE GENOME | estradiol / progesterone | |||
5627 | PROS1 | DRUGGABLE GENOME | lusutrombopag | LUSUTROMBOPAG | ||
5627 | PROS1 | DRUGGABLE GENOME | warfarin | WARFARIN |
Page: 1 2 |